Global GLP-1 Agonist Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
The global GLP-1 Agonist market size is projected to grow from US$ 20150 million in 2022 to US$ 61280 million in 2029; it is expected to grow at a CAGR of 17.2% from 2023 to 2029.
United States market for GLP-1 Agonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for GLP-1 Agonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for GLP-1 Agonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key GLP-1 Agonist players cover Novo Nordisk, AstraZeneca, Sanofi, GSK, Eli Lilly, Zealand Pharma A/S, hansoh and BENEMAE, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
GLP-1 is a polypeptide hormone secreted by the intestine after being stimulated by food. It can stimulate the pancreatic beta cells to secrete insulin and participate in the regulation of blood sugar balance in the human body. However, natural GLP-1 is easily degraded by dipeptidyl peptidase in vivo and loses its activity. In order to make GLP-1 better for clinical application, drug developers have modified its structure and developed a series of GLP-1 receptor agonists. GLP-1 receptor agonists can exert the same biological effects as natural GLP-1, and can also avoid being degraded and inactivated, thereby prolonging the action time.
LPI (LP Information)' newest research report, the “GLP-1 Agonist Industry Forecast” looks at past sales and reviews total world GLP-1 Agonist sales in 2022, providing a comprehensive analysis by region and market sector of projected GLP-1 Agonist sales for 2023 through 2029. With GLP-1 Agonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Agonist industry.
This Insight Report provides a comprehensive analysis of the global GLP-1 Agonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 Agonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global GLP-1 Agonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Agonist and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Agonist.
This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Agonist market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global GLP-1 Agonist market?
What factors are driving GLP-1 Agonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do GLP-1 Agonist market opportunities vary by end market size?
How does GLP-1 Agonist break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
The global GLP-1 Agonist market size is projected to grow from US$ 20150 million in 2022 to US$ 61280 million in 2029; it is expected to grow at a CAGR of 17.2% from 2023 to 2029.
United States market for GLP-1 Agonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for GLP-1 Agonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for GLP-1 Agonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key GLP-1 Agonist players cover Novo Nordisk, AstraZeneca, Sanofi, GSK, Eli Lilly, Zealand Pharma A/S, hansoh and BENEMAE, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
GLP-1 is a polypeptide hormone secreted by the intestine after being stimulated by food. It can stimulate the pancreatic beta cells to secrete insulin and participate in the regulation of blood sugar balance in the human body. However, natural GLP-1 is easily degraded by dipeptidyl peptidase in vivo and loses its activity. In order to make GLP-1 better for clinical application, drug developers have modified its structure and developed a series of GLP-1 receptor agonists. GLP-1 receptor agonists can exert the same biological effects as natural GLP-1, and can also avoid being degraded and inactivated, thereby prolonging the action time.
LPI (LP Information)' newest research report, the “GLP-1 Agonist Industry Forecast” looks at past sales and reviews total world GLP-1 Agonist sales in 2022, providing a comprehensive analysis by region and market sector of projected GLP-1 Agonist sales for 2023 through 2029. With GLP-1 Agonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Agonist industry.
This Insight Report provides a comprehensive analysis of the global GLP-1 Agonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 Agonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global GLP-1 Agonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Agonist and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Agonist.
This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Agonist market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Long-Acting Drug
- Short-Acting Drug
- Diabetes
- Obesity
- Nonalcoholic Fatty Liver Disease
- Metabolic Disorder
- Alzheimer's Disease
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novo Nordisk
- AstraZeneca
- Sanofi
- GSK
- Eli Lilly
- Zealand Pharma A/S
- hansoh
- BENEMAE
What is the 10-year outlook for the global GLP-1 Agonist market?
What factors are driving GLP-1 Agonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do GLP-1 Agonist market opportunities vary by end market size?
How does GLP-1 Agonist break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global GLP-1 Agonist Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for GLP-1 Agonist by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for GLP-1 Agonist by Country/Region, 2018, 2022 & 2029
2.2 GLP-1 Agonist Segment by Type
2.2.1 Long-Acting Drug
2.2.2 Short-Acting Drug
2.3 GLP-1 Agonist Sales by Type
2.3.1 Global GLP-1 Agonist Sales Market Share by Type (2018-2023)
2.3.2 Global GLP-1 Agonist Revenue and Market Share by Type (2018-2023)
2.3.3 Global GLP-1 Agonist Sale Price by Type (2018-2023)
2.4 GLP-1 Agonist Segment by Application
2.4.1 Diabetes
2.4.2 Obesity
2.4.3 Nonalcoholic Fatty Liver Disease
2.4.4 Metabolic Disorder
2.4.5 Alzheimer's Disease
2.4.6 Other
2.5 GLP-1 Agonist Sales by Application
2.5.1 Global GLP-1 Agonist Sale Market Share by Application (2018-2023)
2.5.2 Global GLP-1 Agonist Revenue and Market Share by Application (2018-2023)
2.5.3 Global GLP-1 Agonist Sale Price by Application (2018-2023)
3 GLOBAL GLP-1 AGONIST BY COMPANY
3.1 Global GLP-1 Agonist Breakdown Data by Company
3.1.1 Global GLP-1 Agonist Annual Sales by Company (2018-2023)
3.1.2 Global GLP-1 Agonist Sales Market Share by Company (2018-2023)
3.2 Global GLP-1 Agonist Annual Revenue by Company (2018-2023)
3.2.1 Global GLP-1 Agonist Revenue by Company (2018-2023)
3.2.2 Global GLP-1 Agonist Revenue Market Share by Company (2018-2023)
3.3 Global GLP-1 Agonist Sale Price by Company
3.4 Key Manufacturers GLP-1 Agonist Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers GLP-1 Agonist Product Location Distribution
3.4.2 Players GLP-1 Agonist Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR GLP-1 AGONIST BY GEOGRAPHIC REGION
4.1 World Historic GLP-1 Agonist Market Size by Geographic Region (2018-2023)
4.1.1 Global GLP-1 Agonist Annual Sales by Geographic Region (2018-2023)
4.1.2 Global GLP-1 Agonist Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic GLP-1 Agonist Market Size by Country/Region (2018-2023)
4.2.1 Global GLP-1 Agonist Annual Sales by Country/Region (2018-2023)
4.2.2 Global GLP-1 Agonist Annual Revenue by Country/Region (2018-2023)
4.3 Americas GLP-1 Agonist Sales Growth
4.4 APAC GLP-1 Agonist Sales Growth
4.5 Europe GLP-1 Agonist Sales Growth
4.6 Middle East & Africa GLP-1 Agonist Sales Growth
5 AMERICAS
5.1 Americas GLP-1 Agonist Sales by Country
5.1.1 Americas GLP-1 Agonist Sales by Country (2018-2023)
5.1.2 Americas GLP-1 Agonist Revenue by Country (2018-2023)
5.2 Americas GLP-1 Agonist Sales by Type
5.3 Americas GLP-1 Agonist Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC GLP-1 Agonist Sales by Region
6.1.1 APAC GLP-1 Agonist Sales by Region (2018-2023)
6.1.2 APAC GLP-1 Agonist Revenue by Region (2018-2023)
6.2 APAC GLP-1 Agonist Sales by Type
6.3 APAC GLP-1 Agonist Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe GLP-1 Agonist by Country
7.1.1 Europe GLP-1 Agonist Sales by Country (2018-2023)
7.1.2 Europe GLP-1 Agonist Revenue by Country (2018-2023)
7.2 Europe GLP-1 Agonist Sales by Type
7.3 Europe GLP-1 Agonist Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa GLP-1 Agonist by Country
8.1.1 Middle East & Africa GLP-1 Agonist Sales by Country (2018-2023)
8.1.2 Middle East & Africa GLP-1 Agonist Revenue by Country (2018-2023)
8.2 Middle East & Africa GLP-1 Agonist Sales by Type
8.3 Middle East & Africa GLP-1 Agonist Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of GLP-1 Agonist
10.3 Manufacturing Process Analysis of GLP-1 Agonist
10.4 Industry Chain Structure of GLP-1 Agonist
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 GLP-1 Agonist Distributors
11.3 GLP-1 Agonist Customer
12 WORLD FORECAST REVIEW FOR GLP-1 AGONIST BY GEOGRAPHIC REGION
12.1 Global GLP-1 Agonist Market Size Forecast by Region
12.1.1 Global GLP-1 Agonist Forecast by Region (2024-2029)
12.1.2 Global GLP-1 Agonist Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global GLP-1 Agonist Forecast by Type
12.7 Global GLP-1 Agonist Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk GLP-1 Agonist Product Portfolios and Specifications
13.1.3 Novo Nordisk GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca GLP-1 Agonist Product Portfolios and Specifications
13.2.3 AstraZeneca GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi GLP-1 Agonist Product Portfolios and Specifications
13.3.3 Sanofi GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 GSK
13.4.1 GSK Company Information
13.4.2 GSK GLP-1 Agonist Product Portfolios and Specifications
13.4.3 GSK GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 GSK Main Business Overview
13.4.5 GSK Latest Developments
13.5 Eli Lilly
13.5.1 Eli Lilly Company Information
13.5.2 Eli Lilly GLP-1 Agonist Product Portfolios and Specifications
13.5.3 Eli Lilly GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Eli Lilly Main Business Overview
13.5.5 Eli Lilly Latest Developments
13.6 Zealand Pharma A/S
13.6.1 Zealand Pharma A/S Company Information
13.6.2 Zealand Pharma A/S GLP-1 Agonist Product Portfolios and Specifications
13.6.3 Zealand Pharma A/S GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Zealand Pharma A/S Main Business Overview
13.6.5 Zealand Pharma A/S Latest Developments
13.7 hansoh
13.7.1 hansoh Company Information
13.7.2 hansoh GLP-1 Agonist Product Portfolios and Specifications
13.7.3 hansoh GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 hansoh Main Business Overview
13.7.5 hansoh Latest Developments
13.8 BENEMAE
13.8.1 BENEMAE Company Information
13.8.2 BENEMAE GLP-1 Agonist Product Portfolios and Specifications
13.8.3 BENEMAE GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 BENEMAE Main Business Overview
13.8.5 BENEMAE Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global GLP-1 Agonist Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for GLP-1 Agonist by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for GLP-1 Agonist by Country/Region, 2018, 2022 & 2029
2.2 GLP-1 Agonist Segment by Type
2.2.1 Long-Acting Drug
2.2.2 Short-Acting Drug
2.3 GLP-1 Agonist Sales by Type
2.3.1 Global GLP-1 Agonist Sales Market Share by Type (2018-2023)
2.3.2 Global GLP-1 Agonist Revenue and Market Share by Type (2018-2023)
2.3.3 Global GLP-1 Agonist Sale Price by Type (2018-2023)
2.4 GLP-1 Agonist Segment by Application
2.4.1 Diabetes
2.4.2 Obesity
2.4.3 Nonalcoholic Fatty Liver Disease
2.4.4 Metabolic Disorder
2.4.5 Alzheimer's Disease
2.4.6 Other
2.5 GLP-1 Agonist Sales by Application
2.5.1 Global GLP-1 Agonist Sale Market Share by Application (2018-2023)
2.5.2 Global GLP-1 Agonist Revenue and Market Share by Application (2018-2023)
2.5.3 Global GLP-1 Agonist Sale Price by Application (2018-2023)
3 GLOBAL GLP-1 AGONIST BY COMPANY
3.1 Global GLP-1 Agonist Breakdown Data by Company
3.1.1 Global GLP-1 Agonist Annual Sales by Company (2018-2023)
3.1.2 Global GLP-1 Agonist Sales Market Share by Company (2018-2023)
3.2 Global GLP-1 Agonist Annual Revenue by Company (2018-2023)
3.2.1 Global GLP-1 Agonist Revenue by Company (2018-2023)
3.2.2 Global GLP-1 Agonist Revenue Market Share by Company (2018-2023)
3.3 Global GLP-1 Agonist Sale Price by Company
3.4 Key Manufacturers GLP-1 Agonist Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers GLP-1 Agonist Product Location Distribution
3.4.2 Players GLP-1 Agonist Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR GLP-1 AGONIST BY GEOGRAPHIC REGION
4.1 World Historic GLP-1 Agonist Market Size by Geographic Region (2018-2023)
4.1.1 Global GLP-1 Agonist Annual Sales by Geographic Region (2018-2023)
4.1.2 Global GLP-1 Agonist Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic GLP-1 Agonist Market Size by Country/Region (2018-2023)
4.2.1 Global GLP-1 Agonist Annual Sales by Country/Region (2018-2023)
4.2.2 Global GLP-1 Agonist Annual Revenue by Country/Region (2018-2023)
4.3 Americas GLP-1 Agonist Sales Growth
4.4 APAC GLP-1 Agonist Sales Growth
4.5 Europe GLP-1 Agonist Sales Growth
4.6 Middle East & Africa GLP-1 Agonist Sales Growth
5 AMERICAS
5.1 Americas GLP-1 Agonist Sales by Country
5.1.1 Americas GLP-1 Agonist Sales by Country (2018-2023)
5.1.2 Americas GLP-1 Agonist Revenue by Country (2018-2023)
5.2 Americas GLP-1 Agonist Sales by Type
5.3 Americas GLP-1 Agonist Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC GLP-1 Agonist Sales by Region
6.1.1 APAC GLP-1 Agonist Sales by Region (2018-2023)
6.1.2 APAC GLP-1 Agonist Revenue by Region (2018-2023)
6.2 APAC GLP-1 Agonist Sales by Type
6.3 APAC GLP-1 Agonist Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe GLP-1 Agonist by Country
7.1.1 Europe GLP-1 Agonist Sales by Country (2018-2023)
7.1.2 Europe GLP-1 Agonist Revenue by Country (2018-2023)
7.2 Europe GLP-1 Agonist Sales by Type
7.3 Europe GLP-1 Agonist Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa GLP-1 Agonist by Country
8.1.1 Middle East & Africa GLP-1 Agonist Sales by Country (2018-2023)
8.1.2 Middle East & Africa GLP-1 Agonist Revenue by Country (2018-2023)
8.2 Middle East & Africa GLP-1 Agonist Sales by Type
8.3 Middle East & Africa GLP-1 Agonist Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of GLP-1 Agonist
10.3 Manufacturing Process Analysis of GLP-1 Agonist
10.4 Industry Chain Structure of GLP-1 Agonist
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 GLP-1 Agonist Distributors
11.3 GLP-1 Agonist Customer
12 WORLD FORECAST REVIEW FOR GLP-1 AGONIST BY GEOGRAPHIC REGION
12.1 Global GLP-1 Agonist Market Size Forecast by Region
12.1.1 Global GLP-1 Agonist Forecast by Region (2024-2029)
12.1.2 Global GLP-1 Agonist Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global GLP-1 Agonist Forecast by Type
12.7 Global GLP-1 Agonist Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk GLP-1 Agonist Product Portfolios and Specifications
13.1.3 Novo Nordisk GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca GLP-1 Agonist Product Portfolios and Specifications
13.2.3 AstraZeneca GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi GLP-1 Agonist Product Portfolios and Specifications
13.3.3 Sanofi GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 GSK
13.4.1 GSK Company Information
13.4.2 GSK GLP-1 Agonist Product Portfolios and Specifications
13.4.3 GSK GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 GSK Main Business Overview
13.4.5 GSK Latest Developments
13.5 Eli Lilly
13.5.1 Eli Lilly Company Information
13.5.2 Eli Lilly GLP-1 Agonist Product Portfolios and Specifications
13.5.3 Eli Lilly GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Eli Lilly Main Business Overview
13.5.5 Eli Lilly Latest Developments
13.6 Zealand Pharma A/S
13.6.1 Zealand Pharma A/S Company Information
13.6.2 Zealand Pharma A/S GLP-1 Agonist Product Portfolios and Specifications
13.6.3 Zealand Pharma A/S GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Zealand Pharma A/S Main Business Overview
13.6.5 Zealand Pharma A/S Latest Developments
13.7 hansoh
13.7.1 hansoh Company Information
13.7.2 hansoh GLP-1 Agonist Product Portfolios and Specifications
13.7.3 hansoh GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 hansoh Main Business Overview
13.7.5 hansoh Latest Developments
13.8 BENEMAE
13.8.1 BENEMAE Company Information
13.8.2 BENEMAE GLP-1 Agonist Product Portfolios and Specifications
13.8.3 BENEMAE GLP-1 Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 BENEMAE Main Business Overview
13.8.5 BENEMAE Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. GLP-1 Agonist Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. GLP-1 Agonist Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Long-Acting Drug
Table 4. Major Players of Short-Acting Drug
Table 5. Global GLP-1 Agonist Sales by Type (2018-2023) & (K Units)
Table 6. Global GLP-1 Agonist Sales Market Share by Type (2018-2023)
Table 7. Global GLP-1 Agonist Revenue by Type (2018-2023) & ($ million)
Table 8. Global GLP-1 Agonist Revenue Market Share by Type (2018-2023)
Table 9. Global GLP-1 Agonist Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global GLP-1 Agonist Sales by Application (2018-2023) & (K Units)
Table 11. Global GLP-1 Agonist Sales Market Share by Application (2018-2023)
Table 12. Global GLP-1 Agonist Revenue by Application (2018-2023)
Table 13. Global GLP-1 Agonist Revenue Market Share by Application (2018-2023)
Table 14. Global GLP-1 Agonist Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global GLP-1 Agonist Sales by Company (2018-2023) & (K Units)
Table 16. Global GLP-1 Agonist Sales Market Share by Company (2018-2023)
Table 17. Global GLP-1 Agonist Revenue by Company (2018-2023) ($ Millions)
Table 18. Global GLP-1 Agonist Revenue Market Share by Company (2018-2023)
Table 19. Global GLP-1 Agonist Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers GLP-1 Agonist Producing Area Distribution and Sales Area
Table 21. Players GLP-1 Agonist Products Offered
Table 22. GLP-1 Agonist Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global GLP-1 Agonist Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global GLP-1 Agonist Sales Market Share Geographic Region (2018-2023)
Table 27. Global GLP-1 Agonist Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global GLP-1 Agonist Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global GLP-1 Agonist Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global GLP-1 Agonist Sales Market Share by Country/Region (2018-2023)
Table 31. Global GLP-1 Agonist Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global GLP-1 Agonist Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas GLP-1 Agonist Sales by Country (2018-2023) & (K Units)
Table 34. Americas GLP-1 Agonist Sales Market Share by Country (2018-2023)
Table 35. Americas GLP-1 Agonist Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas GLP-1 Agonist Revenue Market Share by Country (2018-2023)
Table 37. Americas GLP-1 Agonist Sales by Type (2018-2023) & (K Units)
Table 38. Americas GLP-1 Agonist Sales by Application (2018-2023) & (K Units)
Table 39. APAC GLP-1 Agonist Sales by Region (2018-2023) & (K Units)
Table 40. APAC GLP-1 Agonist Sales Market Share by Region (2018-2023)
Table 41. APAC GLP-1 Agonist Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC GLP-1 Agonist Revenue Market Share by Region (2018-2023)
Table 43. APAC GLP-1 Agonist Sales by Type (2018-2023) & (K Units)
Table 44. APAC GLP-1 Agonist Sales by Application (2018-2023) & (K Units)
Table 45. Europe GLP-1 Agonist Sales by Country (2018-2023) & (K Units)
Table 46. Europe GLP-1 Agonist Sales Market Share by Country (2018-2023)
Table 47. Europe GLP-1 Agonist Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe GLP-1 Agonist Revenue Market Share by Country (2018-2023)
Table 49. Europe GLP-1 Agonist Sales by Type (2018-2023) & (K Units)
Table 50. Europe GLP-1 Agonist Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa GLP-1 Agonist Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa GLP-1 Agonist Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa GLP-1 Agonist Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa GLP-1 Agonist Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa GLP-1 Agonist Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa GLP-1 Agonist Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of GLP-1 Agonist
Table 58. Key Market Challenges & Risks of GLP-1 Agonist
Table 59. Key Industry Trends of GLP-1 Agonist
Table 60. GLP-1 Agonist Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. GLP-1 Agonist Distributors List
Table 63. GLP-1 Agonist Customer List
Table 64. Global GLP-1 Agonist Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global GLP-1 Agonist Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas GLP-1 Agonist Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas GLP-1 Agonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC GLP-1 Agonist Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC GLP-1 Agonist Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe GLP-1 Agonist Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe GLP-1 Agonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa GLP-1 Agonist Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa GLP-1 Agonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global GLP-1 Agonist Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global GLP-1 Agonist Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global GLP-1 Agonist Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global GLP-1 Agonist Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Novo Nordisk Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 79. Novo Nordisk GLP-1 Agonist Product Portfolios and Specifications
Table 80. Novo Nordisk GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Novo Nordisk Main Business
Table 82. Novo Nordisk Latest Developments
Table 83. AstraZeneca Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 84. AstraZeneca GLP-1 Agonist Product Portfolios and Specifications
Table 85. AstraZeneca GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. AstraZeneca Main Business
Table 87. AstraZeneca Latest Developments
Table 88. Sanofi Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi GLP-1 Agonist Product Portfolios and Specifications
Table 90. Sanofi GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Sanofi Main Business
Table 92. Sanofi Latest Developments
Table 93. GSK Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 94. GSK GLP-1 Agonist Product Portfolios and Specifications
Table 95. GSK GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. GSK Main Business
Table 97. GSK Latest Developments
Table 98. Eli Lilly Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 99. Eli Lilly GLP-1 Agonist Product Portfolios and Specifications
Table 100. Eli Lilly GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Eli Lilly Main Business
Table 102. Eli Lilly Latest Developments
Table 103. Zealand Pharma A/S Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 104. Zealand Pharma A/S GLP-1 Agonist Product Portfolios and Specifications
Table 105. Zealand Pharma A/S GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Zealand Pharma A/S Main Business
Table 107. Zealand Pharma A/S Latest Developments
Table 108. hansoh Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 109. hansoh GLP-1 Agonist Product Portfolios and Specifications
Table 110. hansoh GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. hansoh Main Business
Table 112. hansoh Latest Developments
Table 113. BENEMAE Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 114. BENEMAE GLP-1 Agonist Product Portfolios and Specifications
Table 115. BENEMAE GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. BENEMAE Main Business
Table 117. BENEMAE Latest Developments
Table 1. GLP-1 Agonist Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. GLP-1 Agonist Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Long-Acting Drug
Table 4. Major Players of Short-Acting Drug
Table 5. Global GLP-1 Agonist Sales by Type (2018-2023) & (K Units)
Table 6. Global GLP-1 Agonist Sales Market Share by Type (2018-2023)
Table 7. Global GLP-1 Agonist Revenue by Type (2018-2023) & ($ million)
Table 8. Global GLP-1 Agonist Revenue Market Share by Type (2018-2023)
Table 9. Global GLP-1 Agonist Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global GLP-1 Agonist Sales by Application (2018-2023) & (K Units)
Table 11. Global GLP-1 Agonist Sales Market Share by Application (2018-2023)
Table 12. Global GLP-1 Agonist Revenue by Application (2018-2023)
Table 13. Global GLP-1 Agonist Revenue Market Share by Application (2018-2023)
Table 14. Global GLP-1 Agonist Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global GLP-1 Agonist Sales by Company (2018-2023) & (K Units)
Table 16. Global GLP-1 Agonist Sales Market Share by Company (2018-2023)
Table 17. Global GLP-1 Agonist Revenue by Company (2018-2023) ($ Millions)
Table 18. Global GLP-1 Agonist Revenue Market Share by Company (2018-2023)
Table 19. Global GLP-1 Agonist Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers GLP-1 Agonist Producing Area Distribution and Sales Area
Table 21. Players GLP-1 Agonist Products Offered
Table 22. GLP-1 Agonist Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global GLP-1 Agonist Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global GLP-1 Agonist Sales Market Share Geographic Region (2018-2023)
Table 27. Global GLP-1 Agonist Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global GLP-1 Agonist Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global GLP-1 Agonist Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global GLP-1 Agonist Sales Market Share by Country/Region (2018-2023)
Table 31. Global GLP-1 Agonist Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global GLP-1 Agonist Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas GLP-1 Agonist Sales by Country (2018-2023) & (K Units)
Table 34. Americas GLP-1 Agonist Sales Market Share by Country (2018-2023)
Table 35. Americas GLP-1 Agonist Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas GLP-1 Agonist Revenue Market Share by Country (2018-2023)
Table 37. Americas GLP-1 Agonist Sales by Type (2018-2023) & (K Units)
Table 38. Americas GLP-1 Agonist Sales by Application (2018-2023) & (K Units)
Table 39. APAC GLP-1 Agonist Sales by Region (2018-2023) & (K Units)
Table 40. APAC GLP-1 Agonist Sales Market Share by Region (2018-2023)
Table 41. APAC GLP-1 Agonist Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC GLP-1 Agonist Revenue Market Share by Region (2018-2023)
Table 43. APAC GLP-1 Agonist Sales by Type (2018-2023) & (K Units)
Table 44. APAC GLP-1 Agonist Sales by Application (2018-2023) & (K Units)
Table 45. Europe GLP-1 Agonist Sales by Country (2018-2023) & (K Units)
Table 46. Europe GLP-1 Agonist Sales Market Share by Country (2018-2023)
Table 47. Europe GLP-1 Agonist Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe GLP-1 Agonist Revenue Market Share by Country (2018-2023)
Table 49. Europe GLP-1 Agonist Sales by Type (2018-2023) & (K Units)
Table 50. Europe GLP-1 Agonist Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa GLP-1 Agonist Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa GLP-1 Agonist Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa GLP-1 Agonist Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa GLP-1 Agonist Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa GLP-1 Agonist Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa GLP-1 Agonist Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of GLP-1 Agonist
Table 58. Key Market Challenges & Risks of GLP-1 Agonist
Table 59. Key Industry Trends of GLP-1 Agonist
Table 60. GLP-1 Agonist Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. GLP-1 Agonist Distributors List
Table 63. GLP-1 Agonist Customer List
Table 64. Global GLP-1 Agonist Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global GLP-1 Agonist Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas GLP-1 Agonist Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas GLP-1 Agonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC GLP-1 Agonist Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC GLP-1 Agonist Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe GLP-1 Agonist Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe GLP-1 Agonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa GLP-1 Agonist Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa GLP-1 Agonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global GLP-1 Agonist Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global GLP-1 Agonist Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global GLP-1 Agonist Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global GLP-1 Agonist Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Novo Nordisk Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 79. Novo Nordisk GLP-1 Agonist Product Portfolios and Specifications
Table 80. Novo Nordisk GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Novo Nordisk Main Business
Table 82. Novo Nordisk Latest Developments
Table 83. AstraZeneca Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 84. AstraZeneca GLP-1 Agonist Product Portfolios and Specifications
Table 85. AstraZeneca GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. AstraZeneca Main Business
Table 87. AstraZeneca Latest Developments
Table 88. Sanofi Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi GLP-1 Agonist Product Portfolios and Specifications
Table 90. Sanofi GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Sanofi Main Business
Table 92. Sanofi Latest Developments
Table 93. GSK Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 94. GSK GLP-1 Agonist Product Portfolios and Specifications
Table 95. GSK GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. GSK Main Business
Table 97. GSK Latest Developments
Table 98. Eli Lilly Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 99. Eli Lilly GLP-1 Agonist Product Portfolios and Specifications
Table 100. Eli Lilly GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Eli Lilly Main Business
Table 102. Eli Lilly Latest Developments
Table 103. Zealand Pharma A/S Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 104. Zealand Pharma A/S GLP-1 Agonist Product Portfolios and Specifications
Table 105. Zealand Pharma A/S GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Zealand Pharma A/S Main Business
Table 107. Zealand Pharma A/S Latest Developments
Table 108. hansoh Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 109. hansoh GLP-1 Agonist Product Portfolios and Specifications
Table 110. hansoh GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. hansoh Main Business
Table 112. hansoh Latest Developments
Table 113. BENEMAE Basic Information, GLP-1 Agonist Manufacturing Base, Sales Area and Its Competitors
Table 114. BENEMAE GLP-1 Agonist Product Portfolios and Specifications
Table 115. BENEMAE GLP-1 Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. BENEMAE Main Business
Table 117. BENEMAE Latest Developments
LIST OF FIGURES
Figure 1. Picture of GLP-1 Agonist
Figure 2. GLP-1 Agonist Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global GLP-1 Agonist Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global GLP-1 Agonist Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. GLP-1 Agonist Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Long-Acting Drug
Figure 10. Product Picture of Short-Acting Drug
Figure 11. Global GLP-1 Agonist Sales Market Share by Type in 2022
Figure 12. Global GLP-1 Agonist Revenue Market Share by Type (2018-2023)
Figure 13. GLP-1 Agonist Consumed in Diabetes
Figure 14. Global GLP-1 Agonist Market: Diabetes (2018-2023) & (K Units)
Figure 15. GLP-1 Agonist Consumed in Obesity
Figure 16. Global GLP-1 Agonist Market: Obesity (2018-2023) & (K Units)
Figure 17. GLP-1 Agonist Consumed in Nonalcoholic Fatty Liver Disease
Figure 18. Global GLP-1 Agonist Market: Nonalcoholic Fatty Liver Disease (2018-2023) & (K Units)
Figure 19. GLP-1 Agonist Consumed in Metabolic Disorder
Figure 20. Global GLP-1 Agonist Market: Metabolic Disorder (2018-2023) & (K Units)
Figure 21. GLP-1 Agonist Consumed in Alzheimer's Disease
Figure 22. Global GLP-1 Agonist Market: Alzheimer's Disease (2018-2023) & (K Units)
Figure 23. GLP-1 Agonist Consumed in Other
Figure 24. Global GLP-1 Agonist Market: Other (2018-2023) & (K Units)
Figure 25. Global GLP-1 Agonist Sales Market Share by Application (2022)
Figure 26. Global GLP-1 Agonist Revenue Market Share by Application in 2022
Figure 27. GLP-1 Agonist Sales Market by Company in 2022 (K Units)
Figure 28. Global GLP-1 Agonist Sales Market Share by Company in 2022
Figure 29. GLP-1 Agonist Revenue Market by Company in 2022 ($ Million)
Figure 30. Global GLP-1 Agonist Revenue Market Share by Company in 2022
Figure 31. Global GLP-1 Agonist Sales Market Share by Geographic Region (2018-2023)
Figure 32. Global GLP-1 Agonist Revenue Market Share by Geographic Region in 2022
Figure 33. Americas GLP-1 Agonist Sales 2018-2023 (K Units)
Figure 34. Americas GLP-1 Agonist Revenue 2018-2023 ($ Millions)
Figure 35. APAC GLP-1 Agonist Sales 2018-2023 (K Units)
Figure 36. APAC GLP-1 Agonist Revenue 2018-2023 ($ Millions)
Figure 37. Europe GLP-1 Agonist Sales 2018-2023 (K Units)
Figure 38. Europe GLP-1 Agonist Revenue 2018-2023 ($ Millions)
Figure 39. Middle East & Africa GLP-1 Agonist Sales 2018-2023 (K Units)
Figure 40. Middle East & Africa GLP-1 Agonist Revenue 2018-2023 ($ Millions)
Figure 41. Americas GLP-1 Agonist Sales Market Share by Country in 2022
Figure 42. Americas GLP-1 Agonist Revenue Market Share by Country in 2022
Figure 43. Americas GLP-1 Agonist Sales Market Share by Type (2018-2023)
Figure 44. Americas GLP-1 Agonist Sales Market Share by Application (2018-2023)
Figure 45. United States GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 46. Canada GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 47. Mexico GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 48. Brazil GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 49. APAC GLP-1 Agonist Sales Market Share by Region in 2022
Figure 50. APAC GLP-1 Agonist Revenue Market Share by Regions in 2022
Figure 51. APAC GLP-1 Agonist Sales Market Share by Type (2018-2023)
Figure 52. APAC GLP-1 Agonist Sales Market Share by Application (2018-2023)
Figure 53. China GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 54. Japan GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 55. South Korea GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 56. Southeast Asia GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 57. India GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 58. Australia GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 59. China Taiwan GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 60. Europe GLP-1 Agonist Sales Market Share by Country in 2022
Figure 61. Europe GLP-1 Agonist Revenue Market Share by Country in 2022
Figure 62. Europe GLP-1 Agonist Sales Market Share by Type (2018-2023)
Figure 63. Europe GLP-1 Agonist Sales Market Share by Application (2018-2023)
Figure 64. Germany GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 65. France GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 66. UK GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 67. Italy GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 68. Russia GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 69. Middle East & Africa GLP-1 Agonist Sales Market Share by Country in 2022
Figure 70. Middle East & Africa GLP-1 Agonist Revenue Market Share by Country in 2022
Figure 71. Middle East & Africa GLP-1 Agonist Sales Market Share by Type (2018-2023)
Figure 72. Middle East & Africa GLP-1 Agonist Sales Market Share by Application (2018-2023)
Figure 73. Egypt GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 74. South Africa GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 75. Israel GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 76. Turkey GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 77. GCC Country GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 78. Manufacturing Cost Structure Analysis of GLP-1 Agonist in 2022
Figure 79. Manufacturing Process Analysis of GLP-1 Agonist
Figure 80. Industry Chain Structure of GLP-1 Agonist
Figure 81. Channels of Distribution
Figure 82. Global GLP-1 Agonist Sales Market Forecast by Region (2024-2029)
Figure 83. Global GLP-1 Agonist Revenue Market Share Forecast by Region (2024-2029)
Figure 84. Global GLP-1 Agonist Sales Market Share Forecast by Type (2024-2029)
Figure 85. Global GLP-1 Agonist Revenue Market Share Forecast by Type (2024-2029)
Figure 86. Global GLP-1 Agonist Sales Market Share Forecast by Application (2024-2029)
Figure 87. Global GLP-1 Agonist Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of GLP-1 Agonist
Figure 2. GLP-1 Agonist Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global GLP-1 Agonist Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global GLP-1 Agonist Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. GLP-1 Agonist Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Long-Acting Drug
Figure 10. Product Picture of Short-Acting Drug
Figure 11. Global GLP-1 Agonist Sales Market Share by Type in 2022
Figure 12. Global GLP-1 Agonist Revenue Market Share by Type (2018-2023)
Figure 13. GLP-1 Agonist Consumed in Diabetes
Figure 14. Global GLP-1 Agonist Market: Diabetes (2018-2023) & (K Units)
Figure 15. GLP-1 Agonist Consumed in Obesity
Figure 16. Global GLP-1 Agonist Market: Obesity (2018-2023) & (K Units)
Figure 17. GLP-1 Agonist Consumed in Nonalcoholic Fatty Liver Disease
Figure 18. Global GLP-1 Agonist Market: Nonalcoholic Fatty Liver Disease (2018-2023) & (K Units)
Figure 19. GLP-1 Agonist Consumed in Metabolic Disorder
Figure 20. Global GLP-1 Agonist Market: Metabolic Disorder (2018-2023) & (K Units)
Figure 21. GLP-1 Agonist Consumed in Alzheimer's Disease
Figure 22. Global GLP-1 Agonist Market: Alzheimer's Disease (2018-2023) & (K Units)
Figure 23. GLP-1 Agonist Consumed in Other
Figure 24. Global GLP-1 Agonist Market: Other (2018-2023) & (K Units)
Figure 25. Global GLP-1 Agonist Sales Market Share by Application (2022)
Figure 26. Global GLP-1 Agonist Revenue Market Share by Application in 2022
Figure 27. GLP-1 Agonist Sales Market by Company in 2022 (K Units)
Figure 28. Global GLP-1 Agonist Sales Market Share by Company in 2022
Figure 29. GLP-1 Agonist Revenue Market by Company in 2022 ($ Million)
Figure 30. Global GLP-1 Agonist Revenue Market Share by Company in 2022
Figure 31. Global GLP-1 Agonist Sales Market Share by Geographic Region (2018-2023)
Figure 32. Global GLP-1 Agonist Revenue Market Share by Geographic Region in 2022
Figure 33. Americas GLP-1 Agonist Sales 2018-2023 (K Units)
Figure 34. Americas GLP-1 Agonist Revenue 2018-2023 ($ Millions)
Figure 35. APAC GLP-1 Agonist Sales 2018-2023 (K Units)
Figure 36. APAC GLP-1 Agonist Revenue 2018-2023 ($ Millions)
Figure 37. Europe GLP-1 Agonist Sales 2018-2023 (K Units)
Figure 38. Europe GLP-1 Agonist Revenue 2018-2023 ($ Millions)
Figure 39. Middle East & Africa GLP-1 Agonist Sales 2018-2023 (K Units)
Figure 40. Middle East & Africa GLP-1 Agonist Revenue 2018-2023 ($ Millions)
Figure 41. Americas GLP-1 Agonist Sales Market Share by Country in 2022
Figure 42. Americas GLP-1 Agonist Revenue Market Share by Country in 2022
Figure 43. Americas GLP-1 Agonist Sales Market Share by Type (2018-2023)
Figure 44. Americas GLP-1 Agonist Sales Market Share by Application (2018-2023)
Figure 45. United States GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 46. Canada GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 47. Mexico GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 48. Brazil GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 49. APAC GLP-1 Agonist Sales Market Share by Region in 2022
Figure 50. APAC GLP-1 Agonist Revenue Market Share by Regions in 2022
Figure 51. APAC GLP-1 Agonist Sales Market Share by Type (2018-2023)
Figure 52. APAC GLP-1 Agonist Sales Market Share by Application (2018-2023)
Figure 53. China GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 54. Japan GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 55. South Korea GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 56. Southeast Asia GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 57. India GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 58. Australia GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 59. China Taiwan GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 60. Europe GLP-1 Agonist Sales Market Share by Country in 2022
Figure 61. Europe GLP-1 Agonist Revenue Market Share by Country in 2022
Figure 62. Europe GLP-1 Agonist Sales Market Share by Type (2018-2023)
Figure 63. Europe GLP-1 Agonist Sales Market Share by Application (2018-2023)
Figure 64. Germany GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 65. France GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 66. UK GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 67. Italy GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 68. Russia GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 69. Middle East & Africa GLP-1 Agonist Sales Market Share by Country in 2022
Figure 70. Middle East & Africa GLP-1 Agonist Revenue Market Share by Country in 2022
Figure 71. Middle East & Africa GLP-1 Agonist Sales Market Share by Type (2018-2023)
Figure 72. Middle East & Africa GLP-1 Agonist Sales Market Share by Application (2018-2023)
Figure 73. Egypt GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 74. South Africa GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 75. Israel GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 76. Turkey GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 77. GCC Country GLP-1 Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 78. Manufacturing Cost Structure Analysis of GLP-1 Agonist in 2022
Figure 79. Manufacturing Process Analysis of GLP-1 Agonist
Figure 80. Industry Chain Structure of GLP-1 Agonist
Figure 81. Channels of Distribution
Figure 82. Global GLP-1 Agonist Sales Market Forecast by Region (2024-2029)
Figure 83. Global GLP-1 Agonist Revenue Market Share Forecast by Region (2024-2029)
Figure 84. Global GLP-1 Agonist Sales Market Share Forecast by Type (2024-2029)
Figure 85. Global GLP-1 Agonist Revenue Market Share Forecast by Type (2024-2029)
Figure 86. Global GLP-1 Agonist Sales Market Share Forecast by Application (2024-2029)
Figure 87. Global GLP-1 Agonist Revenue Market Share Forecast by Application (2024-2029)
